All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of $286.00. Kelly Shi’s rating is based on a ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Please watch the video at Investors ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

BeiGene's drug has been growing fast in the category, with sales rocketing to $233 million in the first half of the year, as use in its approved indications expanded in the US and China and ...

BeiGene, Ltd. (ONC) shares rallied 8.9% in the last trading session to close at $200.99. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

BeiGene has said it intends to resubmit the drug for use by NHS Scotland. The recommendations come 10 months after Brukinsa was approved by the Medicines and Healthcare products Regulatory Agency ...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company ...

SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth ...

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding ...